Articles tagged with Bleeding
Concomitant use of PPIs and antiplatelet drugs is recommended for patients at high risk of GI bleeding who require antiplatelet therapy for heart disease. The balance of risk and benefit favors the use of PPIs together with antiplatelet drugs.
A new anticoagulant drug dabigatran has been found to be equally effective as warfarin in preventing stroke in patients who have previously had a stroke or transient ischaemic attack. The study also showed that dabigatran has a lower risk of intracranial bleeding compared to warfarin.
The Heart and Stroke Foundation of Canada unveiled new Canadian Cardiovascular Society guidelines and position statements at the 2010 Canadian Cardiovascular Congress. These updates aim to support clinicians in practicing evidence-based medicine, with a focus on atrial fibrillation management and antiplatelet therapy.
Researchers have discovered a hemostatic powder that effectively treats bleeding ulcers in up to 95% of patients. The powder's technique is simple and has shown high success rates with minimal complications.
CWRU researcher Erin Lavik is developing synthetic platelets using nanotechnology to treat traumatic injuries. Her lab aims to fine-tune the artificial platelets and integrate them with drug delivery systems.
Patients treated with terlipressin for gastrointestinal bleeding due to portal hypertension experienced a significant reduction in serum sodium concentration. The study suggests that monitoring serum sodium closely and avoiding high-sodium solutions may help prevent adverse events.
Researchers developed a new interventional technique using stent-grafts to control massive bleeding from the hepatic artery after pancreaticoduodenectomy, demonstrating lower mortality rates than conventional surgical intervention. The procedure is considered a valuable alternative for patients with non-portal vein anatomy.
A safety study in 60 stroke patients found minocycline well-tolerated even at three-and-one-half times the dose currently used. The researchers aim to find a dose that can be given easily, regardless of weight, and reduce stroke damage in multiple ways.
A new study published in The Lancet Neurology suggests that cilostazol is at least as effective as aspirin in preventing secondary strokes, but with significantly less major bleeding. The trial involved 2757 patients and found a 26% reduced risk of stroke compared to aspirin.
A double-dose regimen of clopidogrel was found to be more effective than the standard dose in reducing ischemic events and stent thrombosis in patients undergoing PCI for acute coronary syndromes. However, major bleeding increased by 41% with double-dosing.
A recent study published in JAMA found that using lower doses of heparin during coronary procedures does not significantly reduce the risk of major bleeding. The research involved 2,026 patients and compared two dose regimens of adjunctive intravenous unfractionated heparin during PCI in high-risk patients.
The AVERROES study found that apixaban was superior to aspirin for preventing stroke in patients with atrial fibrillation, with a relative risk reduction of over 50% and a small increase in bleeding risk. The study's results will reduce the burden of stroke in society.
Researchers found that standard dose unfractionated heparin (UFH) added to fondaparinux maintains a low rate of major bleeding and prevents catheter thrombosis. The study suggests that standard dose UFH may be the optimal treatment strategy in PCI patients on fondaparinux.
A study found ticagrelor to be more effective than clopidogrel in preventing blood clots, regardless of genetic variations. This means patients with acute coronary syndromes can use ticagrelor instead of clopidogrel, eliminating the need for genetic testing.
A new study found that adherence to practice guidelines reduces bleeding in cirrhosis patients, with 82% of those without bleeding receiving their screening EGD within six months. Patients who did not bleed were more likely to have received their screening EGD within the six-month window compared to those who bled.
High-risk patients undergoing coronary procedures with elective IABP insertion did not experience improved rates of events or death. The study found more minor bleeding in the IABP group, but no significant difference in major bleeding or MACCE.
Researchers at Medical College of Georgia found that daily minocycline treatment can help diabetics avoid strokes or minimize damage by reducing blood vessel remodeling. This could benefit diabetics who are already at increased risk for bleeding and stroke damage.
A new trial shows that administering tranexamic acid to patients with recent, severe bleeding injuries can reduce death rates without increasing adverse effects. The study estimates that up to 100,000 deaths could be prevented annually worldwide.
Pfizer's pre-clinical study on recombinant factor Xa therapy and engineered recombinant factor VIIa molecule shows promising results in restoring hemostasis. The company is committed to advancing hemophilia care through its pipeline and research initiatives.
A multi-institutional study found that extended use of anti-clotting drug enoxaparin significantly reduced the chances of blood clots in bedridden patients, especially those over 75 and female. The treatment also increased bleeding risk slightly.
A new trial shows that Tranexamic acid (TXA) can reduce the risk of death in bleeding trauma patients by 10%, with potential to save up to 100,000 lives per year globally. TXA is a cheap and widely available drug that works by inhibiting clot breakdown, and its inclusion on the WHO list of essential medicines is proposed.
A controlled trial suggests that a combination of band ligation and nadolol may not be the most effective prophylaxis for first variceal bleeding. Beta blockers are generally considered the treatment of choice for prophylaxis of first variceal bleeding.
Use of vascular closure devices and anticoagulant bivalirudin significantly reduced bleeding rates in patients undergoing percutaneous coronary intervention (PCI). Higher-risk patients were less likely to receive these treatments, highlighting the need for targeted interventions.
A Spanish Centre for Pharmacoepidemiological Research study found that slow-release NSAIDs increase the risk of gastrointestinal complications, including GI bleeding and perforation. Long half-life or slow-release formulations were associated with a greater risk.
Researchers examined the impact of uninterrupted clopidogrel on postpolypectomy bleeding rates and found a significant increase in risk when used with aspirin/nonsteroidal anti-inflammatory drugs, but the overall outcome is favorable and the risk is small.
A series of reports find that proton pump inhibitors are associated with increased risk of fractures in postmenopausal women, bacterial infections in many patients, and higher doses do not provide additional benefits for treating bleeding ulcers. Introducing guidelines for proton pump inhibitor use may reduce inappropriate prescriptions.
A joint clinical trial found that administering fibrinogen before heart surgery reduces bleeding risk. The study suggests fibrinogen concentrate could be used as a preventive therapy for patients undergoing cardiac surgery.
A recent study suggests that the risk of brain hemorrhage from unruptured or accidentally discovered brain AVMs may be lower and less severe than initially believed. The Rush University Medical Center's ARUBA trial aims to determine whether a hands-off approach is sufficient for managing these malformations, or if intervention using en...
Researchers found a high prevalence of complications in alcoholic cirrhosis patients at the time of diagnosis, with ascites and variceal bleeding being strong predictors of mortality. The study also showed that these complications do not follow a predictable sequence and cannot be used to determine the clinical course of the disease.
Despite being a common medical emergency, half of UK patients needing emergency investigation for sudden gut bleeding still wait too long for endoscopy. This audit reveals significant delays and underuse of standard treatment, affecting thousands of lives annually.
A Kansas State University study found that Helicobacter infections dramatically change the immune system's response to intestinal damage in trauma patients. This means that therapeutics aimed at stopping complement activation may not be effective for infected individuals, requiring different treatment approaches.
A new study found that lowering the platelet dosage in transfusions can help address frequent shortages in platelet supplies without increasing bleeding risks. The research involved 1,272 patients who received at least one transfusion and reported similar bleeding events regardless of the platelet dose used.
Patients taking warfarin who develop a stroke are at higher risk of brain hemorrhage following intravenous clot-dissolving medication. The study found that the risk was nearly 10-fold higher among warfarin users compared to non-users.
A groundbreaking study led by University of Bristol researchers has shown that a pioneering treatment can significantly reduce disability in premature babies born with serious brain hemorrhages. The treatment, known as ventricular lavage, involves draining out toxic fluids from the brain to improve outcomes for these vulnerable infants.
A new study published in the Lancet finds that apixaban is more effective and convenient than enoxaparin in preventing thromboembolism after knee replacement surgery. The anticoagulant also poses less risk of bleeding, a concern with current treatments. This could lead to better patient outcomes and quality of life.
The discovery reveals QPD is caused by an extra copy of the PLAU gene, leading to overproduction of an enzyme that accelerates blood clot breakdown. This breakthrough genetic test will uncover many more cases and provide fundamental insights into how the uPA gene is controlled.
A study published in the American Journal of Roentgenology found that the risk of major bleeding after image-guided percutaneous biopsies is low, even among patients taking aspirin. The study reviewed 15,181 biopsies performed over six years and found only 70 hemorrhages (0.5%) within three months of biopsy.
The PLATO trial shows that ticagrelor, a stronger anticlotting medication, reduces the risk of cardiovascular death and heart attacks without increasing bleeding in heart attack patients. This new analysis finds significant and clinically relevant reductions in cardiovascular and total deaths, myocardial infarction, and stent thrombosis.
Two large trials found misoprostol tablets non-inferior to intravenous oxytocin for controlling postpartum bleeding, with similar efficacy but increased side effects. The findings support the potential role of misoprostol as a first-line treatment alternative in low-resource settings.
A study published in the World Journal of Gastroenterology found that implanting fibrin sealant combined with ropivacaine in the gallbladder bed effectively controls both visceral and shoulder pain after laparoscopic cholecystectomy. This method provides long-lasting pain relief for patients undergoing this type of surgery.
A team of researchers led by Erin Lavik developed synthetic platelets that show promise in halting internal and external bleeding. The synthetic platelets are designed to home in and link up with natural platelets at the site of an injury, resulting in clotting times about 25% faster than current treatments.
A study of over 40,000 Danish patients found that those taking more than one anti-bleeding medication after a heart attack were at higher risk of non-fatal and fatal bleeding. Non-fatal bleeding was also associated with an increased risk of repeat heart attacks or death.
A study found that 22.3% of dialysis patients receiving percutaneous coronary intervention (PCI) received contraindicated antithrombotic medications, leading to increased rates of in-hospital major bleeding and death. The researchers emphasize the need for educational efforts targeting clinicians and quality improvement interventions.
The American Society for Gastrointestinal Endoscopy has issued new guidelines for managing antithrombotic agents during endoscopic procedures. Aspirin and NSAIDs may be continued for all elective procedures, while temporary anticoagulation therapy should be completed before proceeding.
A new self-assessment score has been developed to predict diabetes risk, showing promise as a simple and effective tool. Additionally, researchers are considering alternative bacteria, Fusobacterium necrophorum, for sore throat treatment due to its association with a rare but life-threatening complication, Lemierre syndrome. Furthermor...
Research highlights the need to address hemophilia treatment disparities in developing countries. A new study from North Carolina State University found that prevalence of hemophilia A has increased over time due to improved treatments, but access to life-saving clotting factor VIII remains severely limited.
A new Mayo Clinic study has found that video capsule endoscopy is safe for patients with heart devices, contradicting previous FDA contraindication. The study, involving 84 patients, showed no complications or interference between the procedure and implanted cardiac devices.
A new study suggests that a shorter course of antibiotics following tonsillectomy may be just as effective in reducing pain and promoting recovery. The research found no significant differences between children who received a 3-day versus 7-day course of postoperative antibiotics.
Researchers at Duke University Medical Center have engineered a way to design drugs and their antidotes together, improving patient care. The new approach allows for the creation of universal antidotes for aptamers, which can reverse the action of any aptamer drug, regardless of sequence, shape, or target.
Dabigatran, a new blood-thinner, has been shown to be as effective as warfarin in preventing strokes and major bleeding, but with significantly fewer side effects. This finding could lead to a change in standard anticoagulant therapy.
A recent clinical trial has found that the combination of clopidogrel and stomach medicines does not lead to adverse events. The COGENT trial involved 3,627 patients and showed a significant reduction in gastrointestinal events with PPI use.
A study ranked obstetrical residency programs based on maternal complication rates, finding that top-quintile programs had significantly lower complication rates compared to bottom-quintile programs. The rankings were consistent across individual types of complications, suggesting that these rates may reflect overall quality.
The HORIZONS-AMI trial showed that bivalirudin therapy significantly reduces major bleeding and cardiac death in patients with ST-segment myocardial infarction (STEMI) who have disease of the left anterior descending (LAD) artery. In high-risk STEMI patients, bivalirudin also provides the greatest mortality benefit.
A study published in the World Journal of Gastroenterology found that underlying malignancy, liver cirrhosis, and hematemesis are key predictors of rebleeding after negative angiographic findings. The research team analyzed 128 patients with acute non-variceal gastrointestinal bleeding who had negative initial angiography results.
The TRIANA trial found primary angioplasty superior to thrombolysis in treating acute myocardial infarction (AMI) in patients aged 75 or older. Primary angioplasty showed a significantly lower need for recurrent cardiac ischemia and comparable outcomes compared to thrombolysis.
Researchers found warfarin therapy reduces ischemic stroke risk but increases intracranial bleeding risk in patients with atrial fibrillation. Benefits of treatment are greatest for patients over 85 years old and those with multiple risk factors for stroke.
The RE-LY study found dabigatran to be more effective than warfarin in preventing stroke in patients with atrial fibrillation. The higher dose of dabigatran significantly reduces stroke risk by 34% compared to warfarin, while the lower dose has a similar effect but with less major bleeding.
The PLATO study demonstrated that ticagrelor reduced cardiovascular events by 16% compared to clopidogrel, with no increase in major bleeding. The efficacy of ticagrelor was observed across all major acute coronary syndromes patient types, with a consistent benefit seen in secondary endpoints.
The HORIZONS-AMI study found that bivalirudin reduced clinical events and major bleeding in heart attack patients undergoing angioplasty. This is a significant finding with important clinical implications for the selection of treatment strategies for high-risk patients.
A phase II trial shows otamixaban, an intravenous blood clot inhibitor, reduces major coronary complications in high-risk ACS patients with lower bleeding rates compared to heparin. The study found intermediate doses of otamixaban offer a significant reduction in death and ischemic complications.